Description

Plasma fractionation is the downstream processing of plasma that has been harvested by donors. It breaks plasma into individual proteins, or plasma fractions. A study by StrategyHelix indicates that the global plasma fractionation market is expected to increase by US$ 13.7 billion from 2022 to 2028, garnering a CAGR of 6.4% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for plasma fractionation. The global plasma fractionation market is segmented on the basis of product, application, end user, and region. Based on product, the global plasma fractionation market is categorized into immunoglobulins, albumins, coagulation factor concentrates, others. The immunoglobulins segment held the largest share of the global plasma fractionation market in 2021 and is anticipated to hold its share during the forecast period. On the basis of application, the global plasma fractionation market has been segmented into neurology, immunology, hematology, others. Globally, the neurology segment made up the largest share of the plasma fractionation market. By end user, the global plasma fractionation market has been segmented into hospitals and clinics, research laboratories, others. The hospitals and clinics segment was the largest contributor to the global plasma fractionation market in 2021. In terms of geography, the global plasma fractionation market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW). North America is estimated to account for the largest share of the global plasma fractionation market.

The global plasma fractionation market is highly competitive. As of 2021, the major players in the global plasma fractionation market were Baxter International Inc., Bio Products Laboratory (BPL), Biotest AG, China Biologic Products Holdings Inc., CSL Ltd., Grifols International S.A., Kedrion SpA, Octapharma AG, Shanghai RAAS Blood Products Co. Ltd.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the plasma fractionation market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: immunoglobulins, albumins, coagulation factor concentrates, others
Application: neurology, immunology, hematology, others
End user: hospitals and clinics, research laboratories, others
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global plasma fractionation market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Plasma fractionation market overview
Part 3. Market breakdown by product
– Immunoglobulins
– Albumins
– Coagulation factor concentrates
– Others
Part 4. Market breakdown by application
– Neurology
– Immunology
– Hematology
– Others
Part 5. Market breakdown by end user
– Hospitals and clinics
– Research laboratories
– Others
Part 6. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 7. Key companies
– Baxter International Inc.
– Bio Products Laboratory (BPL)
– Biotest AG
– China Biologic Products Holdings, Inc.
– CSL Ltd.
– Grifols International S.A.
– Kedrion SpA
– Octapharma AG
– Shanghai RAAS Blood Products Co., Ltd.
About StrategyHelix
Disclaimer